patients are being anticoagulated and fewer are being managed with antiplatelet drugs (ineffective) or anticoagulant /antiplatelet combination (unsafe) therapy. The major challenge is now to complete the clinical development of these agents and to explore ways to improve adherence and persistence to therapy. l
References 1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67.
2. The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. Arch Intern Med 1997;157:1237–40.
3. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005;4:CD001925.
4. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007;3:CD006186.
5. Mant J et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370: 493–503.
6. Connolly SJ et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806–17.
7. Connolly SJ et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011;155:579–86.
8. Savelieva I, Camm AJ. Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol 2014;37:32–47.
9. Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–1151.
10. Patel MR et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–891.
11. Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92.
12. Giugliano RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.
13. Ruff CT et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62.
14. Graham DJ et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients
the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes 2013;6:461–9.
23. Kakkar AK et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One 2013;8:e63479.
24. Eikelboom JW et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206–14.
25. De Caterina R, Camm AJ. What is ‘valvular’ atrial fibrillation? A reappraisal. Eur Heart J 2014;35:3328–35.
26. Camm AJ et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360–420.
treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157–64.
15. Beyer-Westendorf J et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955–62.
16. Beyer-Westendorf J et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non- interventional oral anticoagulation registry. Europace 2015;17:530–8.
17. Nelson WW et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2015;27:1–31.
18. Camm AJ et al. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace 2015;17:1007–17.
19. Steinberg BA et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. J Am Heart Assoc 2013;2:e000535.
20. Kirchhof P et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events – European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6-14.
21. Lip GY et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014;16:308–19.
22. Cullen MW et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from
27. Enriquez A, Lip GY, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace 2015;Mar 26. pii: euv030 [Epub ahead of print].
28. Pollack CV Jr et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373(6):511–20.
29. Glund S et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo- controlled, double-blind phase 1 trial. Lancet 2015;386:680–90.
30. Glund S et al. Idarucizumab, a specific antidote for dabigatran: Immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Oral presentation on 8 December 2014; ASH Meeting.
31. January CT et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130:e199–267.
32. Jones C et al. The management of atrial fibrillation: summary of updated NICE guidance. BMJ 2014;348:g3655.
33. Camm AJ et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europace 2012;14:1385–413.
34. Verma A et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 2014;30:1114–30.
35. Inoue H et al. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 2014;78: 1997–2021.
36. Ogawa S et al. The APHRS’s 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythm 2013;29:190–200.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36